PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
Resource Type
Article
Authors
Akhurst, Tim ; Alipour, Ramin ; Azad, Arun A ; Banks, Patricia ; Beaulieu, Alexis ; Buteau, James P ; Chua, Wei ; Davis, Ian D ; Dhiantravan, Nattakorn ; Emmett, Louise ; Ford, Kate ; Hofman, Michael S ; Francis, Roslyn J ; Gedye, Craig ; Goh, Jeffrey C ; Guminski, Alex ; Hamid, Anis ; Haskali, Mohammad B ; Hicks, Rodney J ; Hsiao, Edward ; Iravani, Amir ; Joshua, Anthony M ; Kirkwood, Ian D ; Kong, Grace ; Kwan, Edmond M ; Langford, Ailsa ; Lawrence, Nicola ; Lee, Sze-Ting ; Lewin, Jeremy ; Lin, Peter ; Martin, Andrew J ; McDonald, William ; McJannett, Margaret M ; Moodie, Kate ; Murphy, Declan G ; Ng, Siobhan ; Pattison, David A ; Pokorski, Izabella ; Ramdave, Shakher ; Ravi Kumar, Aravind S ; Redfern, Andrew D ; Rutherford, Natalie K ; Saghebi, Javad ; Sandhu, Shahneen ; Scott, Andrew M ; Spain, Lavinia ; Stockler, Martin R ; Subramaniam, Shalini ; Tan, Thean Hsiang ; Thang, Sue Ping ; Tran, Ben ; Wallace, Roslyn ; Weickhardt, Andrew ; Williams, Scott G ; Yip, Sonia ; Zhang, Alison Y
Source
In The Lancet Oncology November 2022 23(11):1389-1397
Subject
Primary Research Articles
Language
ISSN
1470-2045